Matt Miksic Stock Analyst Profile - Barclays Research Coverage - Stocknear

Matt Miksic

Stock Analyst at Barclays

(4.52)
# 1502
Out of 5,506 analysts
284
Total ratings
Success rate
Average return

38 Stocks

Name Action PT Current % Upside Ratings Updated
BSX Boston Scientific
Maintains: Overweight
133 136
97.31 39.76% 16 Oct 2, 2025
SENS Senseonics Holdings
Initiates Coverage On: Overweight
2
n/a n/a 1 Aug 27, 2025
HUMA Humacyte
Initiates Coverage On: Overweight
4
2.1 66.67% 1 Aug 27, 2025
LIVN LivaNova
Maintains: Equal-Weight
55 58
53.37 8.68% 8 Aug 21, 2025
PODD Insulet
Maintains: Equal-Weight
266 300
309.12 -2.95% 9 Aug 21, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
53 51
14.71 246.7% 7 Aug 8, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
41 36
23.86 50.88% 18 Aug 4, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
21 22
13.96 57.59% 3 Aug 4, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
24 21
15.15 38.61% 14 Jul 30, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
93 98
67.05 46.16% 7 Jul 30, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
90 95
77.07 23.26% 24 Jul 25, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Equal-Weight
9 19
18.94 0.32% 8 Jul 22, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
165 176
188.64 -6.7% 13 Jul 17, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
19 16
15.2 5.26% 5 Jun 9, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
261 241
193.58 24.5% 1 Jun 3, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
16 12
2.71 342.8% 2 May 5, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
684 635
452.35 40.38% 7 Apr 24, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
158 159
134.58 18.15% 26 Apr 17, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
100 103
60.48 70.3% 15 Feb 24, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Underweight
118 112
100.78 11.13% 7 Feb 10, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
418 443
370.6 19.54% 21 Feb 10, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
22
4.31 410.44% 1 Jan 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
105 109
97.7 11.57% 15 Nov 26, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
56 58
n/a n/a 6 Aug 4, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Equal-Weight
15
n/a n/a 1 Dec 21, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Outperform
96
77.39 24.05% 9 May 13, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Outperform
100
67.03 49.19% 4 May 13, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
722 418
132.17 216.26% 3 May 4, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
31 28
15.95 75.55% 2 Mar 2, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
68 67
13.19 407.96% 1 Mar 1, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
11 4
n/a n/a 4 Jan 7, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
480
7.06 6698.87% 1 Jan 7, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
84 87
14.8 487.84% 14 Nov 3, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
24 25
4.29 482.75% 5 Aug 10, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
200 160
n/a n/a 2 Nov 10, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
26 24
n/a n/a 1 Oct 10, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 1 Jul 10, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Sell
9
7.21 24.83% 1 Dec 12, 2016